{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:41:43Z","timestamp":1784922103313,"version":"3.55.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1002\/hep.31886","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:51:19Z","timestamp":1620467479000},"page":"2290-2292","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["The Glucagon\u2010Like Peptide\u20101 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis"],"prefix":"10.1097","volume":"74","author":[{"given":"Laura E.","family":"Dichtel","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology,Department of Medicine,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"hep31886-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo\u2010controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"hep31886-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of Endocrine Disease: are all GLP\u20101 agonists equal in the treatment of type 2 diabetes?","volume":"181","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"Suppl. 1","key":"hep31886-bib-0003-20250824","first-page":"S111","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"hep31886-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non\u2010alcoholic steatohepatitis (LEAN): a multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep31886-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta\u2010analysis","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31886-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon\u2010like peptide\u20101 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep31886-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep31886-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31886","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31886","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:13:11Z","timestamp":1756077191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31886","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]}}}